HIV Protease Inhibitors

"HIV Protease Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly.

Descriptor ID	D017320
MeSH Number(s)	D27.505.519.389.745.420 D27.505.954.122.388.077.088.420
Concept/Terms	HIV Protease Inhibitors HIV Protease Inhibitors Inhibitors, HIV Protease Protease Inhibitors, HIV

Below are MeSH descriptors whose meaning is more general than "HIV Protease Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Protease Inhibitors [D27.505.519.389.745]
HIV Protease Inhibitors [D27.505.519.389.745.420]
Therapeutic Uses [D27.505.954]
Anti-Infective Agents [D27.505.954.122]
Antiviral Agents [D27.505.954.122.388]
Anti-Retroviral Agents [D27.505.954.122.388.077]
Anti-HIV Agents [D27.505.954.122.388.077.088]
HIV Protease Inhibitors [D27.505.954.122.388.077.088.420]

Below are MeSH descriptors whose meaning is related to "HIV Protease Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "HIV Protease Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "HIV Protease Inhibitors" by people in this website by year, and whether "HIV Protease Inhibitors" was a major or minor topic of these publications.

Bar chart showing 37 publications over 17 distinct years, with a maximum of 5 publications in 2003

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	2	0	2
1997	1	1	2
1998	2	1	3
1999	0	1	1
2000	3	0	3
2002	1	0	1
2003	5	0	5
2004	2	0	2
2006	1	1	2
2007	1	0	1
2008	0	3	3
2009	1	1	2
2010	1	2	3
2012	3	0	3
2013	1	0	1
2016	1	1	2
2025	1	0	1

Below are the most recent publications written about "HIV Protease Inhibitors" by people in Profiles.

Anderson D, Ramgopal M, Hagins DP, Lee J, Simonson RB, Hsu TH, Xu P, Ahmad N, Short WR. DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor-Based Regimen Switch Strategy to Manage Integrase Inhibitor-Related Weight Gain. Clin Infect Dis. 2025 03 17; 80(3):602-612.

View in: PubMed
Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, Avihingsanon A, Koenig E, Jiang S, White K, Cheng A, Szwarcberg J, Cao H. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV. 2016 09; 3(9):e410-e420.

View in: PubMed
Rahangdale L, Cates J, Potter J, Badell ML, Seidman D, Miller ES, Coleman JS, Lazenby GB, Levison J, Short WR, Yawetz S, Ciaranello A, Livingston E, Duthely L, Rimawi BH, Anderson JR, Stringer EM. Integrase inhibitors in late pregnancy and rapid HIV viral load reduction. Am J Obstet Gynecol. 2016 Mar; 214(3):385.e1-7.

View in: PubMed
Squires K, Feinberg J, Bridge DA, Currier J, Ryan R, Seyedkazemi S, Dayaram YK, Mrus J. Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey. AIDS Patient Care STDS. 2013 Jun; 27(6):352-62.

View in: PubMed
Hermes A, Squires K, Fredrick L, Martinez M, Pasley M, Trinh R, Norton M. Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women. HIV Clin Trials. 2012 Nov-Dec; 13(6):308-23.

View in: PubMed
Albert NE, Kazi S, Santoro J, Dougherty R. Ritonavir and epidural triamcinolone as a cause of iatrogenic Cushing's syndrome. Am J Med Sci. 2012 Jul; 344(1):72-4.

View in: PubMed
Smith KY, Garcia F, Kumar P, Currier JS, Ryan R, Falcon R, Mrus J, Squires K. Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE. J Natl Med Assoc. 2012 Jul-Aug; 104(7-8):366-76.

View in: PubMed
Hammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE. A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. HIV Clin Trials. 2010 Nov-Dec; 11(6):312-24.

View in: PubMed
Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, Falcon R, Tennenberg A, Mrus J, Squires K. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010 Sep 21; 153(6):349-57.

View in: PubMed
Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010 Aug 24; 24(13):2019-27.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement